Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
More than 50 years after the introduction of modern pharmacotherapies for schizophrenia, there remains a tremendous need for therapeutic advances. A second generation of antipsychotic drugs, introduced over the past 15 years, has provided uncertain advantages over the first-generation drugs. This paper reviews the designs of studies that evaluate the effectiveness of putative antipsychotic drugs. Data from the trials needed to achieve regulatory approval do not meet all the needs of clinicians and policy makers. Practical and large, simple trials that evaluate the comparative effectiveness of antipsychotic drugs in real-world settings can help to meet these needs once a drug has reached the market.
Stroup
T Scott
TS
Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, North Carolina 27599-7160, USA. sstroup@med.unc.edu
Alves
Wayne M
WM
Hamer
Robert M
RM
Lieberman
Jeffrey A
JA
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy*; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents